-- Scott Roberts
THURSDAY, May 8, 2014 (HealthDay News) -- Zontivity (vorapaxar) tablets have been approved by the U.S. and Drug Administration for people at high risk of heart attack or stroke.
The drug is the first in a new class called protease-activated receptor-1 antagonists, designed to weaken the tendency of platelets to clump and form a blood clot. But the agency said the drug increases users' risks of developing life-threatening bleeding. Zontivity's label includes a boxed warning describing this risk, the FDA said Thursday in a news release.
The drug is meant for people who have had a previous heart attack or blocked arteries in the arms or legs. It should not be used by people who have had a prior stroke, "mini-stroke" or a prior episode of bleeding in the head, the agency warned.
The most common side effects include bleeding and bruising. Users who have these side effects should report them immediately to their doctors, the FDA advised.
Zontivity is made by Merck Sharp and Dohme Corp., whose parent Merck & Co. is based in Whitehouse Station, N.J.
Visit the FDA to learn more.
EBSCO Information Services is fully accredited by URAC. URAC is an independent, nonprofit health care accrediting organization dedicated to promoting health care quality through accreditation, certification and commendation.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Information Services. All rights reserved.